Outcome According to Clinical and Biological Parameters in 42 Patients With t(11;14): Uniparameter Analysis
| Variable . | No. Patients . | Median Survival (Months) . | 95% Confidence Interval . | P . |
|---|---|---|---|---|
| Age yr | ||||
| ≤60 | 13 | 34 | 24-44 | .92 |
| >60 | 29 | 40 | 29-52 | |
| LDH | ||||
| Normal | 23 | 43 | 33-54 | .069 |
| Increased | 18 | 29 | 17-40 | |
| Sex | ||||
| f | 13 | 61 | 49-73 | .006 |
| m | 29 | 31 | 21-42 | |
| Splenomegaly | ||||
| yes | 19 | 33 | 21-45 | .184 |
| no | 23 | 47 | 33-61 | |
| PB involvement | ||||
| no | 11 | 33 | 20-45 | .71 |
| yes | 31 | 47 | 30-52 | |
| BM involvement | ||||
| yes | 27 | 47 | 34-59 | .026 |
| no | 15 | 25 | 17-32 | |
| Primary site of involvement | ||||
| lymph node | 28 | 28 | 21-36 | .015 |
| BM ± spleen | 14 | 55 | 40-71 | |
| Stage | ||||
| advanced | 31 | 34 | 25-43 | .107 |
| initial | 11 | 54 | 33-75 | |
| PS (ECOG) | ||||
| 0-1 | 36 | 42 | 28-56 | .121 |
| 2-4 | 6 | 19 | 7-31 | |
| Serum albumin | ||||
| <4.0 | 29 | 43 | 30-55 | .45 |
| ≥4.0 | 13 | 34 | 21-47 | |
| +12 by FISH | ||||
| yes | 12 | 22 | 13-30 | .006 |
| no | 30 | 47 | 36-59 | |
| 17p by FISH | ||||
| yes | 11 | 28 | 18-39 | .073 |
| no | 31 | 45 | 33-57 | |
| 13q by FISH | ||||
| yes | 22 | 30 | 22-38 | .053 |
| no | 20 | 48 | 33-64 | |
| CCA | ||||
| 1 | 21 | 64 | 50-78 | |
| 2 | 7 | 24 | 18-30 | .0001 |
| 3 | 14 | 12 | 8-16 | |
| CCA + FISH | ||||
| 1 | 11 | 86* | Not reached at 86 months | |
| 2 | 14 | 48 | 36-60 | <.0001 |
| 3 | 17 | 15 | 9-21 |
| Variable . | No. Patients . | Median Survival (Months) . | 95% Confidence Interval . | P . |
|---|---|---|---|---|
| Age yr | ||||
| ≤60 | 13 | 34 | 24-44 | .92 |
| >60 | 29 | 40 | 29-52 | |
| LDH | ||||
| Normal | 23 | 43 | 33-54 | .069 |
| Increased | 18 | 29 | 17-40 | |
| Sex | ||||
| f | 13 | 61 | 49-73 | .006 |
| m | 29 | 31 | 21-42 | |
| Splenomegaly | ||||
| yes | 19 | 33 | 21-45 | .184 |
| no | 23 | 47 | 33-61 | |
| PB involvement | ||||
| no | 11 | 33 | 20-45 | .71 |
| yes | 31 | 47 | 30-52 | |
| BM involvement | ||||
| yes | 27 | 47 | 34-59 | .026 |
| no | 15 | 25 | 17-32 | |
| Primary site of involvement | ||||
| lymph node | 28 | 28 | 21-36 | .015 |
| BM ± spleen | 14 | 55 | 40-71 | |
| Stage | ||||
| advanced | 31 | 34 | 25-43 | .107 |
| initial | 11 | 54 | 33-75 | |
| PS (ECOG) | ||||
| 0-1 | 36 | 42 | 28-56 | .121 |
| 2-4 | 6 | 19 | 7-31 | |
| Serum albumin | ||||
| <4.0 | 29 | 43 | 30-55 | .45 |
| ≥4.0 | 13 | 34 | 21-47 | |
| +12 by FISH | ||||
| yes | 12 | 22 | 13-30 | .006 |
| no | 30 | 47 | 36-59 | |
| 17p by FISH | ||||
| yes | 11 | 28 | 18-39 | .073 |
| no | 31 | 45 | 33-57 | |
| 13q by FISH | ||||
| yes | 22 | 30 | 22-38 | .053 |
| no | 20 | 48 | 33-64 | |
| CCA | ||||
| 1 | 21 | 64 | 50-78 | |
| 2 | 7 | 24 | 18-30 | .0001 |
| 3 | 14 | 12 | 8-16 | |
| CCA + FISH | ||||
| 1 | 11 | 86* | Not reached at 86 months | |
| 2 | 14 | 48 | 36-60 | <.0001 |
| 3 | 17 | 15 | 9-21 |
Abbreviations: CCA, patients subdivided in group 1, 2, 3 based solely on conventional cytogenetics; CCA + FISH, group 1, 2, and 3 compiled using metaphase banding analysis and interphase cytogenetic data.